<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336092">
  <stage>Registered</stage>
  <submitdate>15/10/2010</submitdate>
  <approvaldate>19/10/2010</approvaldate>
  <actrnumber>ACTRN12610000883011</actrnumber>
  <trial_identification>
    <studytitle>Comparative assessment of the absorption of a generic  formulatons of darifenacin against the innovator darifenacin product in healthy volunteers.</studytitle>
    <scientifictitle>Bioequivalence assessment of generic darifenacin [Darisec(R - registered trademark) ] vs. innovator darifenacin [Enablex(R - registered trademak)] in healthy volunteers.</scientifictitle>
    <utrn>U1111-1117-4887</utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Bioequivalence assessment between two formulations of darifenacin</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Simultaneous admininstration of Darifenacin, Darisec(R - registered trademark) 7.5 mg p.o. , single dose, cross over study design with one week wash out period in between.</interventions>
    <comparator>Simultaneous administration of Darifenacin, Enablex(R - registered trademark) 7.5 mg p.o. single dose  cross over study design with one week wash out period in between.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Area Under the Curve concentration of Darifenacin/time (AUC0-t and AUC0-inf).
Darifenacin plasma concentration will be measured with a Liquid Chromatography-Mass Spectrometry method and concentration vs. time curves will be plotted
Area Under the Curve (AUC0-t) will be calculated using the trapezoidal rule.
AUC0-inf will be calculated extrapolating the last cocentration point to infinity using the log-linear elimination rate constant method.</outcome>
      <timepoint>0, 0:30, 1, 2, 3, 4,  5, 6, 7, 8, 10, 12, 24, 36, 48 and 72 hours.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum concentration (Cmax). 
Darifenacinn plasma concentration will be measured with a Liquid Chromatography-Mass Spectrometry method and concentration vs. time curves will be plotted
Peak concentration (Cmax) will be directly taken  from the darifenacin plasma concentration vs. time curve.</outcome>
      <timepoint>0, 0:30, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 and 72 hours.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to peak concentrarion (Cmax) . 
It is measured on the abscissa from time 0 to the Cmax time.</outcome>
      <timepoint>0, 0:30, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 48 and 72 hours.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Caucasians
BMI&gt;18.5 and &lt;29.9 kg/m2
Healthy based in medical history, physical examination, 12-lead ECG and clinical laboratory evaluations.
Able to comply wiht study procedures. 
Able to give informed written consent for participation in the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Known hypersensitivity or idiosyncratic reaciton to darifenacin or any related drug.
Resting heart rate &gt; 70 bpm.
Pregnant or breast-feeding.
Ingestion of medicines at any time within 14 days before the inception of the trial.
A recent history of alcoholism (&lt;2 years) or of moderate alcohol use (180 ml/day), or consumption of alcohol within 48 hours prior to the start of the study.
Smoker, more than 10 ciegarrettes per day.
Presence of clinically significant abnormal laboratory values during screening.
History of drug addiction or testing positive in pre-study drug scan.
Donation of blood (350 ml) within 90 days prior to receiving the study drug.
History of psychiatric disorder.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation was concealed using numbered containers.</concealment>
    <sequence>Computarised sequence generation.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Bio-equivalence</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>15/11/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Uruguay</country>
      <state>Montevideo</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Center for Clinical Pharmacology Research Bdbeq S.A.</primarysponsorname>
    <primarysponsoraddress>Br. Artigas1632. cp 11600, Montevideo</primarysponsoraddress>
    <primarysponsorcountry>Uruguay</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>ELEA S.A.C.I.F. y A.</fundingname>
      <fundingaddress>Sanabria 2353 - C1417AZE - Ciudad de Buenos Aires - Argentina.</fundingaddress>
      <fundingcountry>Argentina</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objective of the present trial is to assess the bioequivalence of a new formulation of extended release darifenacin -Darisec (R) 7.5 mg- vs.  the innovator -Enablex(R) 7.5 mg- ; both given orally within 30 minutes of  a high fat breakfast  to healthy volunteers.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Comite de Etica en la Investigaci?n. Universidad Catolica.</ethicname>
      <ethicaddress>8 de Octubre 2738. 11600 Montevideo</ethicaddress>
      <ethicapprovaldate>13/09/2010</ethicapprovaldate>
      <hrec>A.05.09.10</hrec>
      <ethicsubmitdate />
      <ethiccountry>Uruguay</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Francisco E. Estevez-Carrizo</name>
      <address>Hospital Italiano.
Br. Artigas 1632. 
cp 11600. Montevideo</address>
      <phone>+59824876288</phone>
      <fax />
      <email>francisco.estevez@bdbeq.com.uy</email>
      <country>Uruguay</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Susana Parrillo</name>
      <address>Hospital Italiano. 
Br. Artigas1632.
cp 11600 Montevideo.</address>
      <phone>+59824876288</phone>
      <fax />
      <email>sparrillo@bdbeq.com.uy</email>
      <country>Uruguay</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Francisco E. Estevez-Carrizo</name>
      <address>Br. Artigas 1632. cp 11600. Montevideo</address>
      <phone>+59824876288</phone>
      <fax />
      <email>francisco.estevez@bdbeq.com.uy</email>
      <country>Uruguay</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>